Cereno Scientific AB (publ)

OM:CRNO B Stock Report

Market Cap: SEK 1.5b

Cereno Scientific Management

Management criteria checks 1/4

Cereno Scientific's CEO is Sten Sorensen, appointed in Jan 2015, has a tenure of 9.92 years. total yearly compensation is SEK7.35M, comprised of 38% salary and 62% bonuses, including company stock and options. directly owns 0.39% of the company’s shares, worth SEK5.71M. The average tenure of the management team and the board of directors is 2 years and 1.5 years respectively.

Key information

Sten Sorensen

Chief executive officer

SEK 7.3m

Total compensation

CEO salary percentage38.0%
CEO tenure9.9yrs
CEO ownership0.4%
Management average tenure2yrs
Board average tenure1.5yrs

Recent management updates

Recent updates

Is Cereno Scientific (STO:CRNO B) Using Debt Sensibly?

Sep 26
Is Cereno Scientific (STO:CRNO B) Using Debt Sensibly?

Will Cereno Scientific (STO:CRNO B) Spend Its Cash Wisely?

Sep 01
Will Cereno Scientific (STO:CRNO B) Spend Its Cash Wisely?

We're Keeping An Eye On Cereno Scientific's (NGM:CRNO B) Cash Burn Rate

Apr 05
We're Keeping An Eye On Cereno Scientific's (NGM:CRNO B) Cash Burn Rate

CEO Compensation Analysis

How has Sten Sorensen's remuneration changed compared to Cereno Scientific's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-SEK 81m

Jun 30 2024n/an/a

-SEK 69m

Mar 31 2024n/an/a

-SEK 59m

Dec 31 2023SEK 7mSEK 3m

-SEK 48m

Sep 30 2023n/an/a

-SEK 35m

Jun 30 2023n/an/a

-SEK 31m

Mar 31 2023n/an/a

-SEK 27m

Dec 31 2022SEK 2mSEK 2m

-SEK 28m

Compensation vs Market: Sten's total compensation ($USD665.22K) is above average for companies of similar size in the Swedish market ($USD232.03K).

Compensation vs Earnings: Sten's compensation has increased whilst the company is unprofitable.

CEO

Sten Sorensen (65 yo)

9.9yrs

Tenure

SEK 7,347,000

Compensation

Mr. Sten R. Sorensen serves as Director of Cereno Scientific AB (publ) since April 16, 2024. He serves as Director of SynAct Pharma AB since March 20, 2024. He serves as the Chief Executive Officer at Cere...

Leadership Team

NamePositionTenureCompensationOwnership
Sten Sorensen
CEO & Director9.9yrsSEK 7.35m0.39%
SEK 5.7m
Jonas Saljo
Chief Intellectual Property Officer5.5yrsSEK 893.00kno data
Eva Jagenheim
Chief Financial Officer1.3yrsno data0.098%
SEK 1.4m
Bjorn Dahlof
Chief Scientific Officer2yrsSEK 96.00k0.55%
SEK 8.1m
Henrik Westdahl
Director of Communications & IRless than a yearno datano data
Tove Bergenholt
Director of Communications & IR (currently on parental leave)less than a yearno datano data
Fredrik Frick
Head of Clinical Operations2.6yrsno datano data
Nicholas Oakes
Head of Preclinical Development2.3yrsno datano data
Rahul Agrawal
Chief Medical Officer & Head of R&Dless than a yearno datano data

2.0yrs

Average Tenure

58yo

Average Age

Experienced Management: CRNO B's management team is considered experienced (2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sten Sorensen
CEO & Directorless than a yearSEK 7.35m0.39%
SEK 5.7m
Bertram Pitt
Chairman of Scientific Advisory Boardno datano datano data
Deepak Bhatt
Member of Scientific Advisory Boardno datano datano data
Jeppe Ovlesen
Director1.1yrsSEK 18.00k0.020%
SEK 285.9k
Gordon Williams
Member of Scientific Advisory Boardno datano datano data
Anders Svensson
Director6.2yrsSEK 917.00k0.17%
SEK 2.5m
Gunnar Olsson
Director & Member of Scientific Advisory Boardless than a yearno datano data
Raymond Benza
Member of Scientific Advisory Board3.9yrsno datano data
Faiez Zannad
Member of Scientific Advisory Boardno datano datano data
Joakim Soderstrom
Chairperson1.9yrsSEK 2.61m0.57%
SEK 8.4m

1.5yrs

Average Tenure

63.5yo

Average Age

Experienced Board: CRNO B's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 12:33
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cereno Scientific AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jyoti PrakashEdison Investment Research
Soo RomanoffEdison Investment Research